Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.3%

Neg 0% Neu 84.3% Pos 0%

Needham analyst Gil Blum reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $6 price target.

Comments

No comments yet. Be the first!